Symbols / SNCA
SNCA Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
—
Low
—
High
—
Mean
—
- Parkinson Disease SNCA Risk Variants Are Associated With Higher Asymmetric Putamen Dopaminergic Dysfunction - Neurology® Journals Fri, 07 Nov 2025 22
- Glycerol 3-phosphate acyltransferase exacerbates α-synuclein-induced toxicity by increasing lipid peroxidation - Nature Mon, 19 Jan 2026 08
- $2.2 Billion Parkinson's Breakthrough: Arrowhead's Novel Brain Drug Platform Attracts Major Novartis Deal - Stock Titan ue, 02 Sep 2025 07
- Arrowhead and Novartis sign agreement for ARO-SNCA - BioWorld MedTech Wed, 03 Sep 2025 07
- Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license - Reuters ue, 02 Sep 2025 07
- Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Business Wire ue, 25 Nov 2025 08
- Arrowhead Pharmaceuticals Partners with Novartis for ARO-SNCA - TipRanks ue, 02 Sep 2025 07
- Novartis pays $200M for Arrowhead's Parkinson's RNA therapy - drugdiscoverytrends.com ue, 02 Sep 2025 07
- Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ - Stocktwits ue, 02 Sep 2025 07
- Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion - Investor's Business Daily ue, 02 Sep 2025 07
- Novartis invests US$200min lacklustre Parkinson’s target - European Biotechnology Magazine Wed, 03 Sep 2025 07
- Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com Fri, 05 Sep 2025 12
- RiboTAC Targets “Undruggable” Parkinson’s Protein, α-Synuclein - GEN - Genetic Engineering and Biotechnology News Mon, 01 Jan 2024 08
- Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding - Nature hu, 15 Sep 2022 07
- Resequencing the complete SNCA locus in Indian patients with Parkinson’s disease - Nature Mon, 15 Apr 2024 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SNCA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|